Scientists have edited a gene that may reduce high cholesterol permanently

Dangerously high levels of “bad” cholesterol and triglycerides may be reduced by gene editing, in what study researchers hope ...
TCTMD

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.

Vote to provide $3 billion for dementia institute a 'game-changer' for Texas researchers, families

Texas voters' approval of Proposition 14 during Tuesday’s election is a boon for research into dementia, Alzheimer’s, and ...

Voters’ anger over high electricity bills and data centers loom over 2026 midterms

Voter anger over rising electricity costs is shaping next year's midterm elections. Communities with fast-rising electric ...

Study finds outpatient dialysis program cuts emergency hospital visits in Texas

The cost of emergency dialysis is estimated to be eight times that of in-center dialysis. A new study reveals that a ...

Cleveland Clinic gets $2M subsidy for maternity care in Indian River County

A $2 million subsidy will benefit Indian River County residents and Indian River Hospital caregivers and the hospital, a ...
ABC13 Houston on MSN

Harris Health to hear from public on acquiring part of Hermann Park to expand Ben Taub Hospital

Harris Health asks the community to submit questions and comments regarding the acquisition of part of Hermann Park before two upcoming town halls.
The American Journal of Managed Care

Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol

Navar A. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with or at-risk for ASCVD: the phase 3 CORALreef lipids trial. Presented at: AHA 2025 ...